miRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance

Multiple myeloma (MM) produces clonal plasma cells and aberrant monoclonal antibody accumulation in patients’ bone marrow (BM). Around 1% of all cancers and 13% of hematological malignancies are caused by MM, making it one of the most common types of cancer. Diagnostic and therapeutic methods for ma...

Full description

Saved in:
Bibliographic Details
Published inTechnology in Cancer Research & Treatment Vol. 22; p. 15330338231202391
Main Authors Tavakoli Pirzaman, Ali, Ebrahimi, Pouyan, Hasanpour, Amir Hossein, Shakeri, Mahdi, Babajani, Bahareh, Pourali Ganji, Zahra, Babaei, Hedye, Rahmati, Amirhossein, Hosseinzadeh, Rezvan, Doostmohamadian, Shahrbanoo, Kazemi, Sohrab
Format Book Review Journal Article
LanguageEnglish
Published Los Angeles, CA SAGE Publications 01.01.2023
Sage Publications Ltd
SAGE Publishing
Subjects
Bone Marrow - pathology
Drug Resistance
Gene Expression Regulation, Neoplastic
Humans
Malignancy
MicroRNAs
MicroRNAs - genetics
miRNA
Monoclonal antibodies
Multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - genetics
Multiple Myeloma - therapy
Plasma cells
Prognosis
Review
pathogenesis
miRNA
multiple myeloma
drug resistance
prognosis
Online AccessGet full text

Cover

More Information
Summary:Multiple myeloma (MM) produces clonal plasma cells and aberrant monoclonal antibody accumulation in patients’ bone marrow (BM). Around 1% of all cancers and 13% of hematological malignancies are caused by MM, making it one of the most common types of cancer. Diagnostic and therapeutic methods for managing MM are currently undergoing extensive research. MicroRNAs (miRNAs) are short noncoding RNAs that reduce or inhibit the translation of their target mRNA after transcription. Because miRNAs play an influential role in how myeloma develops, resources, and becomes resistant to drugs, miRNA signatures may be used to diagnose, do prognosis, and treat the myeloma response. Consequently, researchers have investigated the levels of miRNA in plasma cells from MM patients and developed tools to test whether they directly impacted tumor growth. This review discusses the latest discoveries in miRNA science and their role in the development of MM. We also emphasize the potential applications of miRNAs to diagnose, prognosticate, and treat MM in the future.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1533-0346
1533-0338
DOI:10.1177/15330338231202391